Anticancer drug targets: Approaching angiogenesis

Journal of Clinical Investigation

Volumn 104, Issue 11, 1999, Pages 1497-1501

  Keshet, Eli ^a   Ben Sasson, Shmuel A ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; CANCER THERAPY; CELL ADHESION; CELL PROLIFERATION; CELL SPECIFICITY; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MUTATION; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR GROWTH; VASCULAR ENDOTHELIUM;

EID: 0033454716     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI8849     Document Type: Review

References (27)

1. Folkman, J. 1971. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285:1182-1186.
2. Rak, J., Filmus, J., and Kerbel, R.S. 1996. Reciprocal paracrine interaccions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. Eur. J. Cancer. 32A:2438-2450.
3. Hanahan, D., and Folkman, J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353-364.
4. Ohh, M., et. al. 1999. Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. J. Clin. Invest. 104:1583-1591
5. Perez-Atayde, A.R., et al. 1997. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol. 150:815-821.
6. Good, D.J., et al. 1990. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl Acad. Sci. USA. 87:6624-6628.
7. Pasqualini, R., and Ruoslahti, E. 1996. Organ targeting in vivo using phage display peptide libraries. Nature. 380:364-366.
8. Ellerby, H.M., et al. 1999. Anti-cancer activity of targeted proapoptotic peptides. Nat. Med. 5:1032-1038.
9. Friedlander, M., et al. 1995. Definition of two angiogenic pathways by distinct αv integrins. Science. 270:1500-1502.
10. Kim, K.J., et al. 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 362:841-844.
11. Fong, T.A., et al. 1999. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59:99-106.
12. Carmeliet, P., et al. 1998. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature. 394:485-490.
13. Benjamin, L., Golijanin, D., Itin, A., Pode, D., and Keshet, E. 1999. Selective ablation of immature blood vessels in established human rumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest 103:159-165.
14. O'Reilly, M.S., et al. 1994. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:315-328.
15. O'Reilly, M.S., et al. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:277-285.
16. O'Reilly, M.S., Holmgren, L., Chen, C., and Folkman, J. 1996. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2:689-692.
17. Bergers, G., Javaherian, K., Lo, K.M., Folkman, J., and Hanahan, D. 1999. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 284:808-812.
18. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M.S. 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:404-407
19. Gately, S., et al. 1997. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc. Natl Acad. Sci. USA. 94:10868-10872.
20. Liotta, L.A., Steeg, P.S., and Stetler-Stevenson, W.G. 1991. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 64:327-336.
21. Vu, T.H., et al. 1998. MMp-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 93:411-422.
22. Stetler-Stevenson, W.G., 1999. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J. Clin. Invest. 103:1237-1241.
23. Elicieri, B.P., and Cheresh, D.A. 1999. The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J. Clin. Invest. 103:1227-1230.
24. Holash, J., et al. 1999. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 284:1994-1998.
25. Maniotis, A.J., et al. 1999. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 155:739-752.
26. Gale, N.W., and Yancopoulos, G.D. 1999. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev. 13:1055-1066.
27. Vlodavsky, I., et al. 1999. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat. Med. 5:793-802.